{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:35:11Z","timestamp":1789522511957,"version":"build-2803163510"},"reference-count":26,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM25\/00052"],"award-info":[{"award-number":["CM25\/00052"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM24\/00223"],"award-info":[{"award-number":["CM24\/00223"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR22\/00049"],"award-info":[{"award-number":["JR22\/00049"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR24\/00011"],"award-info":[{"award-number":["JR24\/00011"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"award":["CM25\/00052"],"award-info":[{"award-number":["CM25\/00052"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}]},{"award":["CM24\/00223"],"award-info":[{"award-number":["CM24\/00223"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JR22\/00049"],"award-info":[{"award-number":["JR22\/00049"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JR24\/00011"],"award-info":[{"award-number":["JR24\/00011"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Consejer\u00eda de Salud y Consumo","doi-asserted-by":"publisher","award":["B-0056-2024"],"award-info":[{"award-number":["B-0056-2024"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]},{"award":["B-0056-2024"],"award-info":[{"award-number":["B-0056-2024"]}],"id":[{"id":"https:\/\/ror.org\/047pymx40","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Objective: Given the increasing use of outpatient parenteral antimicrobial therapy (OPAT) and the clinical challenges posed by Pseudomonas aeruginosa infections, this study aimed to evaluate the effectiveness and safety of OPAT for the treatment of P. aeruginosa infections in a real-world cohort. Methods: We conducted a prospective observational study with retrospective analysis including adult patients with P. aeruginosa infections treated within a multidisciplinary OPAT program shared by two tertiary hospitals between November 2012 and December 2024. Clinical characteristics, infection type, antimicrobial therapy, resistance patterns, source control, and clinical outcomes were recorded. Primary outcomes were treatment failure during OPAT and within 30 days after OPAT completion. Secondary outcomes included adverse events and vascular access complications. Bivariate and multivariable logistic regression analyses were performed to identify factors associated with treatment failure. Results: A total of 290 patients were included. The most frequent infections were bronchiectasis exacerbations (39.7%) and complicated urinary tract infections (15.2%). Most patients received monotherapy (72.8%), mainly ceftazidime, while 27.2% received combination therapy with a beta-lactam plus an aminoglycoside. Treatment failure occurred in 7.6% of patients during OPAT and in 15.5% within 30 days after OPAT completion, with an overall clinical success rate of 77%. Male sex and chronic obstructive pulmonary disease (COPD) were independently associated with failure during OPAT. At 30 days, higher Charlson comorbidity index, COPD exacerbation, and endovascular infection were associated with failure, whereas combination therapy was associated with a lower risk of failure. Antimicrobial-related adverse events were rare (3.2%). Conclusions: Our results support OPAT as an effective and safe strategy for managing P. aeruginosa infections in clinically stable patients. Patients with COPD, either as a comorbidity or during an exacerbation, and those with a higher Charlson score may require closer follow-up.<\/jats:p>","DOI":"10.3390\/pharmaceutics18050549","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:03:47Z","timestamp":1777536227000},"page":"549","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outpatient Parenteral Antimicrobial Therapy for Pseudomonas aeruginosa Infections: Effectiveness and Safety"],"prefix":"10.3390","volume":"18","author":[{"given":"Paloma","family":"Su\u00e1rez-Casillas","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Farmacia, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-4966","authenticated-orcid":false,"given":"Marta","family":"Mej\u00edas-Trueba","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Farmacia, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"},{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Parasitolog\u00eda (UCEIMP), Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Mart\u00ednez Alemany","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario Virgen Macarena, 41004 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola","family":"Navarro Amuedo","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Parasitolog\u00eda (UCEIMP), Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Praena Segovia","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Parasitolog\u00eda (UCEIMP), Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4548-4462","authenticated-orcid":false,"given":"Ar\u00edstides","family":"de Alarc\u00f3n Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Parasitolog\u00eda (UCEIMP), Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7563-5815","authenticated-orcid":false,"given":"Rafael","family":"Luque M\u00e1rquez","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Parasitolog\u00eda (UCEIMP), Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1713-6807","authenticated-orcid":false,"given":"Zaira R.","family":"Palacios-Baena","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario Virgen Macarena, 41004 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Carmona-Caballero","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Parasitolog\u00eda (UCEIMP), Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"S\u00e1nchez Oliva","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Parasitolog\u00eda (UCEIMP), Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Gil-Navarro","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Farmacia, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Garc\u00eda Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Parasitolog\u00eda (UCEIMP), Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-944X","authenticated-orcid":false,"given":"Laura","family":"Herrera-Hidalgo","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Farmacia, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"},{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Parasitolog\u00eda (UCEIMP), Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2749-355X","authenticated-orcid":false,"given":"Manuel","family":"Poyato Borrego","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Parasitolog\u00eda (UCEIMP), Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-527X","authenticated-orcid":false,"given":"Luis E.","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario Virgen Macarena, 41004 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5001-672X","authenticated-orcid":false,"given":"Jos\u00e9 M.","family":"Cisneros","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Parasitolog\u00eda (UCEIMP), Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, 41013 Seville, Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"dlae111","DOI":"10.1093\/jacamr\/dlae111","article-title":"Outpatient parenteral antimicrobial therapy (OPAT) across the world: A comparative analysis-what lessons can we learn?","volume":"6","author":"Reidy","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy745","article-title":"2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/cid\/ciac298","article-title":"Outpatient Versus Inpatient Intravenous Antimicrobial Therapy: A Population-Based Observational Cohort Study of Adverse Events and Costs","volume":"75","author":"Staples","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2024.02.006","article-title":"Barriers and facilitators for the implementation and expansion of outpatient parenteral antimicrobial therapy: A systematic review","volume":"147","author":"Mohammed","year":"2024","journal-title":"J. Hosp. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Schwartz, B., Klamer, K., Zimmerman, J., Kale-Pradhan, P.B., and Bhargava, A. (2024). Multidrug Resistant Pseudomonas aeruginosa in Clinical Settings: A Review of Resistance Mechanisms and Treatment Strategies. Pathogens, 13.","DOI":"10.3390\/pathogens13110975"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/978-3-031-08491-1_16","article-title":"How to Manage Pseudomonas aeruginosa Infections","volume":"1386","author":"Jacot","year":"2022","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_7","unstructured":"EUCAST (2021). To Clinical Colleagues on Recent Changes in Clinical Microbiology Susceptibility Reports, European Committee on Antimicrobial Susceptibility Testing."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Aitken, S.L., Bonomo, R.A., Mathers, A.J., van Duin, D., and Clancy, C.J. (2023). Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin. Infect. Dis., ciad428.","DOI":"10.1093\/cid\/ciad428"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/QCO.0000000000000966","article-title":"MDR\/XDR\/PDR or DTR? Which definition best fits the resistance profile of Pseudomonas aeruginosa?","volume":"36","author":"Cosentino","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13256-017-1221-7","article-title":"Severe skull base osteomyelitis caused by Pseudomonas aeruginosa with successful outcome after prolonged outpatient therapy with continuous infusion of ceftazidime and oral ciprofloxacin: A case report","volume":"11","year":"2017","journal-title":"J. Med. Case Rep."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Venuti, F., Gaviraghi, A., De Nicol\u00f2, A., Stroffolini, G., Longo, B.M., Di Vincenzo, A., Ranzani, F.A., Quaranta, M., Romano, F., and Catellani, E. (2023). Real-Life Experience of Continuously Infused Ceftolozane\/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Pseudomonas aeruginosa Infection in the Outpatient Setting. Antibiotics, 12.","DOI":"10.3390\/antibiotics12071214"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jgar.2021.04.015","article-title":"Continuous infusion, therapeutic drug monitoring and outpatient parenteral antimicrobial therapy with ceftazidime\/avibactam: A retrospective cohort study","volume":"26","author":"Goncette","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ofaa409","DOI":"10.1093\/ofid\/ofaa409","article-title":"Outpatient Parenteral Antimicrobial Therapy With Ceftolozane\/Tazobactam via Continuous Infusion for Multidrug-Resistant Pseudomonas aeruginosa Osteomyelitis","volume":"7","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2471\/BLT.07.045120","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"85","author":"Altman","year":"2007","journal-title":"Bull. World Health Organ."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8610","DOI":"10.1038\/s41598-021-88179-7","article-title":"Outpatient therapy with piperacillin\/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection","volume":"11","author":"Ferreiro","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/23744235.2024.2387130","article-title":"Effectiveness and safety of Ceftolozane\/Tazobactam administered in continuous infusion through elastomeric pumps in OPAT regimen: A case series","volume":"56","author":"Giuliano","year":"2024","journal-title":"Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"ofaa014","DOI":"10.1093\/ofid\/ofaa014","article-title":"Clinical and Safety Evaluation of Continuously Infused Ceftolozane\/Tazobactam in the Outpatient Setting","volume":"7","author":"Jones","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"T153","DOI":"10.1016\/j.farma.2024.03.011","article-title":"[Translated article] Retrospective study of home antibiotic infusion therapy using elastomeric infusion pumps","volume":"48","year":"2024","journal-title":"Farm. Hosp."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e13022","DOI":"10.1111\/ijcp.13022","article-title":"Effectiveness and safety of outpatient parenteral antimicrobial therapy in acute exacerbation of chronic obstructive pulmonary disease","volume":"71","year":"2017","journal-title":"Int. J. Clin. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10096-024-04921-9","article-title":"Outpatient parenteral antibiotic therapy in non-cystic fibrosis lung transplant recipients: Characteristics, efficacy and safety","volume":"44","author":"Forier","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.37201\/req\/122.2020","article-title":"Continuous infusion of antibiotics using elastomeric pumps in the hospital at home setting","volume":"34","year":"2021","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"dlae015","DOI":"10.1093\/jacamr\/dlae015","article-title":"Successful outpatient parenteral antibiotic therapy with cefiderocol for osteomyelitis caused by multi-drug resistant Gram-negative bacteria: A case report","volume":"6","author":"Schellong","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"905.e1","DOI":"10.1016\/j.cmi.2018.11.009","article-title":"Developing a risk prediction model for 30-day unplanned hospitalization in patients receiving outpatient parenteral antimicrobial therapy","volume":"25","author":"Durojaiye","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/resp.14041","article-title":"Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact","volume":"26","author":"MacLeod","year":"2021","journal-title":"Respirology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmi.2024.12.036","article-title":"What is the most effective antibiotic monotherapy for severe Pseudomonas aeruginosa infection? A systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Babich","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000501085","article-title":"Outpatient Parenteral Antimicrobial Treatment for Non-Cystic Fibrosis Bronchiectasis Exacerbations: A Prospective Multicentre Observational Cohort Study","volume":"98","author":"Praena","year":"2019","journal-title":"Respiration"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/5\/549\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:13:08Z","timestamp":1779207188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/5\/549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["pharmaceutics18050549"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18050549","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}